Private Advisor Group LLC boosted its stake in Zoetis Inc (NYSE:ZTS) by 78.2% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 32,295 shares of the company’s stock after buying an additional 14,173 shares during the period. Private Advisor Group LLC’s holdings in Zoetis were worth $2,957,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors also recently modified their holdings of the business. Valeo Financial Advisors LLC grew its stake in shares of Zoetis by 34.4% in the second quarter. Valeo Financial Advisors LLC now owns 2,210 shares of the company’s stock worth $202,000 after purchasing an additional 566 shares in the last quarter. Dupont Capital Management Corp grew its stake in shares of Zoetis by 2.5% in the second quarter. Dupont Capital Management Corp now owns 24,508 shares of the company’s stock worth $2,088,000 after purchasing an additional 601 shares in the last quarter. Rehmann Capital Advisory Group grew its stake in shares of Zoetis by 40.5% in the second quarter. Rehmann Capital Advisory Group now owns 2,190 shares of the company’s stock worth $187,000 after purchasing an additional 631 shares in the last quarter. Wrapmanager Inc. grew its stake in shares of Zoetis by 7.9% in the second quarter. Wrapmanager Inc. now owns 9,176 shares of the company’s stock worth $782,000 after purchasing an additional 672 shares in the last quarter. Finally, Sequoia Financial Advisors LLC grew its stake in shares of Zoetis by 23.0% in the second quarter. Sequoia Financial Advisors LLC now owns 3,746 shares of the company’s stock worth $319,000 after purchasing an additional 700 shares in the last quarter. 89.68% of the stock is currently owned by hedge funds and other institutional investors.
Shares of ZTS stock opened at $95.27 on Friday. Zoetis Inc has a fifty-two week low of $68.56 and a fifty-two week high of $96.57. The stock has a market cap of $44.57 billion, a P/E ratio of 39.70, a PEG ratio of 1.83 and a beta of 0.97. The company has a quick ratio of 2.63, a current ratio of 4.06 and a debt-to-equity ratio of 3.04.
Zoetis (NYSE:ZTS) last announced its earnings results on Thursday, November 1st. The company reported $0.83 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.77 by $0.06. Zoetis had a return on equity of 75.51% and a net margin of 20.35%. The business had revenue of $1.48 billion during the quarter, compared to analysts’ expectations of $1.46 billion. During the same quarter last year, the business posted $0.65 earnings per share. The company’s quarterly revenue was up 9.9% on a year-over-year basis. As a group, sell-side analysts predict that Zoetis Inc will post 3.11 EPS for the current fiscal year.
The business also recently declared a quarterly dividend, which will be paid on Monday, December 3rd. Investors of record on Tuesday, November 20th will be given a $0.126 dividend. The ex-dividend date is Monday, November 19th. This represents a $0.50 dividend on an annualized basis and a dividend yield of 0.53%. Zoetis’s dividend payout ratio (DPR) is 20.83%.
In related news, CEO Juan Ramon Alaix sold 150,306 shares of the stock in a transaction on Thursday, November 8th. The stock was sold at an average price of $94.96, for a total value of $14,273,057.76. Following the completion of the transaction, the chief executive officer now owns 246,319 shares in the company, valued at approximately $23,390,452.24. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Catherine A. Knupp sold 46,816 shares of the stock in a transaction on Wednesday, August 15th. The shares were sold at an average price of $90.84, for a total value of $4,252,765.44. Following the completion of the transaction, the insider now owns 81,640 shares of the company’s stock, valued at approximately $7,416,177.60. The disclosure for this sale can be found here. Insiders sold a total of 350,507 shares of company stock valued at $32,579,830 in the last quarter. 0.35% of the stock is currently owned by corporate insiders.
Several research analysts have recently issued reports on ZTS shares. JPMorgan Chase & Co. raised Zoetis from a “neutral” rating to an “overweight” rating and set a $100.00 price target for the company in a research note on Monday, October 15th. Cantor Fitzgerald reissued a “buy” rating and issued a $98.00 price target on shares of Zoetis in a research note on Monday, October 1st. Stifel Nicolaus cut Zoetis from a “buy” rating to a “hold” rating and set a $95.00 price target for the company. in a research note on Tuesday, August 21st. They noted that the move was a valuation call. Zacks Investment Research raised Zoetis from a “hold” rating to a “buy” rating and set a $101.00 price target for the company in a research note on Monday, September 10th. Finally, Morgan Stanley set a $100.00 target price on Zoetis and gave the company a “hold” rating in a research note on Friday, November 2nd. Seven research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $93.19.
Zoetis, Inc discovers, develops and manufactures a portfolio of animal health medicines and vaccines. Its products are complemented by diagnostic products, genetic tests, bio devices and services. These are designed to meet the needs of veterinarians and the livestock farmers and companion animal. The firm provides its services though five categories namely, anti-invectives, vaccines, parasitic ides, medicated feed additives, and other pharmaceuticals.
Featured Story: Balanced Fund
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc (NYSE:ZTS).
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.